Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Drew Provan

Showing results (11-20 of 85) with videos related to

Pageof 9
Sort By:
Advances in Therapy|October 27, 2015
Current Management of Primary Immune ThrombocytopeniaDrew Provan, Adrian C Newland
Expert Opinion on Investigational Drugs|May 9, 2022
Investigational drugs for immune thrombocytopeniaDrew Provan, Adrian C Newland
Current Opinion in Hematology|October 16, 2007
Immune thrombocytopenic purpura in adultsBertrand Godeau, Drew Provan, James Bussel
Blood Reviews|May 15, 2025
The new era of primary immune thrombocytopenia management in adults: A narrative review of current and emerging treatmentsTomás José González-López, Drew Provan
Advances in Therapy|April 8, 2022
Proposal for a New Protocol for the Management of Immune Thrombocytopenia (ITP)Tomás José González-López, Drew Provan
BMJ (Clinical Research Ed.)|August 20, 2005
Preventing severe infection after splenectomyAdrian Newland, Drew Provan, Steven Myint
Medicina (Kaunas, Lithuania)|April 28, 2023
Sustained Remission Off-Treatment (SROT) of TPO-RAs: The Burgos Ten-Step Eltrombopag Tapering SchemeTomás José González-López, Drew Provan
Expert Opinion on Biological Therapy|May 21, 2013
Immune thrombocytopenia -- what are the new treatment options?Simon Hallam, Drew Provan, Adrian C Newland
British Journal of Haematology|September 22, 2023
The role of T cells and myeloid-derived suppressor cells in refractory immune thrombocytopeniaKarina Yazdanbakhsh, Drew Provan, John W Semple
British Journal of Haematology|March 17, 2010
A novel missense mutation c.470 A>C (p.D157A) in the SLC40A1 gene as a cause of ferroportin disease in a family with hyperferritinaemiaKhalid Saja, Patricia Bignell, Kathryn Robson, et al.
Pageof 9

Showing results (11-20 of 85) with videos related to

Sort By:
Pageof 9
Advances in Therapy|October 27, 2015
Current Management of Primary Immune ThrombocytopeniaDrew Provan, Adrian C Newland
Expert Opinion on Investigational Drugs|May 9, 2022
Investigational drugs for immune thrombocytopeniaDrew Provan, Adrian C Newland
Current Opinion in Hematology|October 16, 2007
Immune thrombocytopenic purpura in adultsBertrand Godeau, Drew Provan, James Bussel
Blood Reviews|May 15, 2025
The new era of primary immune thrombocytopenia management in adults: A narrative review of current and emerging treatmentsTomás José González-López, Drew Provan
Advances in Therapy|April 8, 2022
Proposal for a New Protocol for the Management of Immune Thrombocytopenia (ITP)Tomás José González-López, Drew Provan
BMJ (Clinical Research Ed.)|August 20, 2005
Preventing severe infection after splenectomyAdrian Newland, Drew Provan, Steven Myint
Medicina (Kaunas, Lithuania)|April 28, 2023
Sustained Remission Off-Treatment (SROT) of TPO-RAs: The Burgos Ten-Step Eltrombopag Tapering SchemeTomás José González-López, Drew Provan
Expert Opinion on Biological Therapy|May 21, 2013
Immune thrombocytopenia -- what are the new treatment options?Simon Hallam, Drew Provan, Adrian C Newland
British Journal of Haematology|September 22, 2023
The role of T cells and myeloid-derived suppressor cells in refractory immune thrombocytopeniaKarina Yazdanbakhsh, Drew Provan, John W Semple
British Journal of Haematology|March 17, 2010
A novel missense mutation c.470 A>C (p.D157A) in the SLC40A1 gene as a cause of ferroportin disease in a family with hyperferritinaemiaKhalid Saja, Patricia Bignell, Kathryn Robson, et al.
Pageof 9